ReviewCancer biology & therapy2015
Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
Review in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04276025 (Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Relationship Between Histopathological Features, Mutation Status, 18F-FDG PET/CT Radiomic Imaging Parameters as Well as Clinical Outcome in Patients With Treatment-naïve Non-small Cell Lung Cancer
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- Multiclass Machine Learning-Based Discovery of Novel Scaffold Inhibitors Targeting ALK.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A structure-based virtual screening approach to identify novel anaplastic lymphoma kinase inhibitors.Journal of molecular modeling · 2026Article
- Durable response to ALK inhibition in low-allele-frequencyFrontiers in oncology · 2026Article
- TFCP2 Fusion-Positive Rhabdomyosarcomas: A Report of 10 Cases and a Review of the Literature.Cancers · 2025Article
- Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.Cancers · 2022Review
- ChiTaH: a fast and accurate tool for identifying known human chimeric sequences from high-throughput sequencing data.NAR genomics and bioinformatics · 2021Article
- Monomerization of ALK Fusion Proteins as a Therapeutic Strategy inFrontiers in oncology · 2020Article
- Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods.Genome biology · 2019Article
- Error Tolerance of Machine Learning Algorithms across Contemporary Biological Targets.Molecules (Basel, Switzerland) · 2019Article
- Double amplifications of CDK4 and MDM2 in a gastric inflammatory myofibroblastic tumor mimicking cancer with local invasion of the spleen and diaphragm.Cancer biology & therapy · 2018Article
- A Rare Case of ALK-Positive Large B-Cell Lymphoma with CD33 Expression.Case reports in hematology · 2018Article
- Article
- Metastatic spread of solid subtype lung adenocarcinoma to the small intestine with anemia and melena: A case report.Medicine · 2017Article
- Lung Cancer Biomarkers.Hematology/oncology clinics of North America · 2017Review
- Relationship and interactions of curcumin with radiation therapy.World journal of clinical oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK) is correlated with oncogenesis in different types of cancers, such as anaplastic large cell lymphoma, lung cancer, neuroblastoma, and even breast cancer, by abnormal fusion of ALK or non-fusion ALK activation. ALK is a receptor tyrosine kinase, with a single transmembrane domain, that plays an important role in development. Upon ligand binding to the extracellular domain, the receptor undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. In recent years, ALK inhibitors have been developed for cancer treatment. These inhibitors target ALK activity and show effectiveness in ALK-positive non-small cell lung cancer. However, acquired treatment resistance makes the future of this therapy unclear; new strategies are underway to overcome the limitations of current ALK inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.